Alliance Pharma plc 12.9% potential upside indicated by RBC Capital Markets

Alliance Pharma plc with ticker (LON:APH) now has a potential upside of 12.9% according to RBC Capital Markets.



RBC Capital Markets set a target price of 121 GBX for the company, which when compared to the Alliance Pharma plc share price of 105 GBX at opening today (01/02/2022) indicates a potential upside of 12.9%. Trading has ranged between 82 (52 week low) and 123 (52 week high) with an average of 641,144 shares exchanging hands daily. The market capitalisation at the time of writing is £602,812,560.

Alliance Pharma plc is a United Kingdom-based holding company. The Company is primarily engaged in the acquisition, marketing and distribution of healthcare and pharmaceutical products. It is focused on two areas, which include Consumer Healthcare brands and Prescription Medicines. The Company’s Consumer Healthcare brands include Kelo-Cote, Nizoral, Amberen, MacuShield, Vamousse and Aloclair. Its Prescription Medicines include Hydromol, Flamma Franchise and Forceval. Its brands also include Ashton & Parsons and Anbesol. The Company’s products include Alliance Calcium Syrup, Amantadine hydrochloride, Aiweidi, Biodermatin, Biotaches, Buccastem M, Changmin, Decapional, Dermachronic, Dermacide, Dervida, Effadiane, Fazol, Gen-Ongles, Irenat, ISIB, Isocarboxazid, Jonctum, Kelo-Stretch, Lypsyl, Lefuzhi, Malunjunshe, MolluDab, Menadiol, Neostigmine and Nu-Seals. Its geographical area includes Europe, Middle East and Africa (EMEA), Asia Pacific and China (APAC) and Americas (AMER).